



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, United States

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com <http://www.wjgnet.com>

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 9816

Title: Biological therapy for ulcerative colitis: an update

Reviewer code: 00042073

Science editor: Ya-Juan Ma

Date sent for review: 2014-03-01 19:41

Date reviewed: 2014-04-29 23:36

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

its a nice review short need futures studies.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, United States

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 9816

Title: Biological therapy for ulcerative colitis: an update

Reviewer code: 02934445

Science editor: Ya-Juan Ma

Date sent for review: 2014-03-01 19:41

Date reviewed: 2014-05-6 23:36

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Please find the comments to the manuscript send to me for review. I apologize for the delay in reply.

Following are my comments :

It is short communication on the recent trend in recombinant protein area for the treatment of Ulcerative colitis (UC)

1. The review gives a brief overview of the current biological therapies available for UC in the area of therapeutic proteins
2. As mentioned by the authors that the study covers the mechanism of action, clinical outcomes and future prospects of four mabs but I find the paper does not cover any of these in details. So I would request the authors to mention that “ It is an attempt to give a brief overview and the current developments in the area of therapeutics for UC”
3. Overall it is a good attempt by them to cover the recent knowledge for the treatment of UCs
4. It gives a crisp information on what is new in the area of biotherapeutics.

I request the editors to accept the paper with few minor changes as suggested.